We help our clients respond to changes in medical evidence and clinical practice
Includes the latest research from ECCO. Understand the treatment landscape for Crohn's disease, including our visual Treatment Map, product opportunities and future market scenarios. Learn about the most significant treatment challenges faced by physicians, including:
New data was presented at ECCO’s 6th Annual Congress from the SUCCESS trial studying the use of infliximab, azathioprine, and infliximab & azathioprine combination in moderate-to-severe ulcerative colitis.
Evidence released at ECCO 2011 from a trial studying the use of ciclosporin vs. infliximab in severe refractory ulcerative colitis will significantly impact current treatment practices.
Our analysts recently attended the ACR 2011 Scientific Meeting in Chicago. We summarized the key papers in our blog and have selected the topics most significant for clinical practice to discuss with our panel of KOLs in our next round of primary research. These include:
Available individually or as part of a series, our premium reports help you understand the treatment landscape.
We highlight the treatment challenges that physicians face and explore commercial opportunities and future scenarios for the pharmaceutical industry.
Treatment Pulse is our online business intelligence service that provides strategic and tactical support by tracking new medical evidence, analyzing its impact on clinical practice through primary research with key opinion-leading doctors and providing in-depth analysis for our clients.